Ono Pharmaceutical Stock

Ono Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the research and development of neuroscience, intracellular signaling, and genomic-based drugs. The company intends to acquire commercialization rights to new drug candidates in early development stages, coordinating with Ono Pharma USA, Inc. and Ono Pharma UK Ltd. in order to expand the development pipeline.

New Drugs in Development

Recalbon Tablets: Recalbon, a drug for the treatment of osteoporosis, is one of the bisphosphonates, preventing bone resorption at low doses and increasing in bone mineral density.

Emend Capsules: Emend is a neurokinin (NK) 1 antagonist. The drug is effective not only for acute phase of chemotherapy-induced nausea and vomiting, but also for delayed phase.

Glactiv Tablets: Glactiv, a dipeptidyl-peptidase (DPP) IV inhibitor, is a new class of drug for type II diabetes and would be useful for control of postprandial hyperglycemia with low risks of hypoglycemia and weight gain in type II diabetes patients.

ONO-2540 / ENA713D (transdermal patch): ONO-2540 or rivastigmine patch is a drug for the treatment of Alzheimer’s disease with an inhibitory action on both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). The drug inhibits not only AChE which is known as an enzyme deeply involved in Alzheimer’s disease, but also BuChE which increases as the disease progresses.

Arocyte for Injection: Arocyte is a drug to prevent expansion of cerebral infarction by improving function of astrocyte, a kind of glial cells in the brain.

Cereact Capsules: Cereact is a drug with a novel mechanism of action for the treatment of neurodegenerative diseases. It inhibits the occurrence and progression of neurodegenerative diseases, such as the ‘intractable’ disease amyotrophic lateral sclerosis (ALS), by improving the abnormal activation of astrocytes.

ONO-7643 / RC-1291 (tablet): ONO-7643 is a small-molecule ghrelin mimetic being developed for cancer anorexia / cachexia. The drug has similar pharmacological actions to ghrelin, a circulating peptide hormone with multiple physiological actions, including appetite stimulation, muscle-building (anabolic), and modulation of gastrointestinal functions.

ONO-5334 (tablet): ONO-5334, a cathepsin K inhibitor, is being developed for osteoporosis with a novel mechanism of action.

ONO-4538 / MDX-1106 (injection): ONO-4538, a fully human anti-PD-1 antibody, would be a treatment for cancer and other diseases. PD-1 is one of the receptors expressed on activated lymphocytes, and is involved in the negative regulatory system to suppress the activated lymphocytes.

ONO-8539 (tablet): ONO-8539 is a selective antagonist of EP1, one of subtype receptors of prostaglandin E2, and overactive bladder is the first indication for its clinical development program.

ONO-4641 (tablet): ONO-4641 is a sphingosine-1-phosphate (S1P) receptor agonist, being developed for the treatment of multiple sclerosis. The drug is a low molecular weight substance that keeps lymphocytes in lymph nodes and reduces the lymphocyte count in the blood, as a result inhibiting the infiltration of lymphocytes into lesions.

ONO-7847 / MK-0517 (injection): ONO-7847 is a neurokinin (NK) 1 receptor antagonist, the prodrug of ONO-7436 (Emend Capsule) available in injectable form.

ONO-5920 / YM529 (tablet): ONO-5920 / YM529 is an intermittent oral version of Recalbon Tablets, a drug for the treatment of osteoporosis.

History

Ono Pharmaceutical Co., Ltd. was founded in 1717.